Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2019

01-06-2019 | Research Article

The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial

Authors: N. Kouhi Habibi, A. Shabestani Monfared, K. Ebrahimnejad Gorji, M. Karimi, A. A. Moghadamnia, M. Tourani, S. Borzoueisileh, F. Niksirat

Published in: Clinical and Translational Oncology | Issue 6/2019

Login to get access

Abstract

Purpose

We aimed to examine the radioprotective effects of melatonin on the blood cell counts of patients with rectum cancer undergoing radiotherapy.

Materials and methods

This double-blind placebo-controlled study was conducted on 60 rectal cancer patients who were referred to Rajaii Hospital of Babolsar, Iran. An equal number of patients were randomly assigned to the control group which received placebo and study group which received 20 mg melatonin a day as an intervention. The melatonin was administered 5 days a week for 28 days. Blood samples were taken before melatonin received on day 1 and also day 28; then, to measure the changes in blood cell counts representing our primary outcomes, the samples were analyzed by Sysmex K810i auto-analyzer.

Results

Our results showed that the platelet, white blood cells, lymphocyte, and neutrophil population reduction induced by radiotherapy were slighter or even insignificant in melatonin recipients compared to control. However, the difference between red blood cells in both groups was not significant.

Conclusion

Our results are indicating that melatonin could prevent or minimize the unfavorable effects of radiotherapy on blood cell count reductions by attenuating the adverse influence of radiation, probably through stimulation of cellular antioxidant potential as previously reported in animal models.

Iranian Registry of Clinical Trials (IRCT)

Registry No. IRCT2016021626586N1.
Literature
1.
Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell. 1998;94(6):703–14.CrossRefPubMed
2.
Matsubara N. Colorectal cancers developed from proximal and distal tumor location belong to the distinct genetic entity and show different oncologic behavior. Molecular diagnosis and targeting for thoracic and gastrointestinal malignancy. New York: Springer; 2018. p. 81–91.
3.
Aran V, Victorino AP, Thuler LC, Ferreira CG. Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality. Clin Colorectal Cancer. 2016;15(3):195–203.CrossRefPubMed
4.
Monastyrska E, Hagner W, Jankowski M, Głowacka I, Zegarska B, Zegarski W. Prospective assessment of the quality of life in patients treated surgically for rectal cancer with lower anterior resection and abdominoperineal resection. Eur J Surg Oncol. 2016;42(11):1647–53.CrossRefPubMed
5.
Balch GC, De Meo A, Guillem JG. Modern management of rectal cancer: a 2006 update. World J Gastroenterol WJG. 2006;12(20):3186.CrossRefPubMed
6.
Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014–20.CrossRefPubMed
7.
8.
Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413–8.CrossRefPubMed
9.
Reiter RJ, Tan DX, Herman TS, Thomas CR. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys. 2004;59(3):639–53.CrossRefPubMed
10.
Scholes G. Radiation effects on DNA. The Silvanus Thompson Memorial Lecture, April 1982. Br J Radiol. 1983;56(664):221–31.CrossRefPubMed
11.
Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist. 2010;15(4):360–71.CrossRefPubMedPubMedCentral
12.
Elgazzar AH, Kazem N. Biological effects of ionizing radiation. The pathophysiologic basis of nuclear medicine. New York: Springer; 2015. p. 715–26.
13.
Meltz ML, Reiter RJ, Herman TS, Kumar S. Melatonin and protection from whole-body irradiation: survival studies in mice. Mutat Res Fundam Mol Mech Mutagenesis. 1999;425(1):21–7.CrossRef
14.
Champney TH, Allen GC, Zannelli M, Beausang LA. Time-dependent effects of melatonin on immune measurements in male Syrian hamsters. J Pineal Res. 1998;25(3):142–6.CrossRefPubMed
15.
De Montigny C, Aghajanian G. Preferential action of 5-methoxytryptamine and 5-methoxydimethyltryptamine on presynaptic serotonin receptors: a comparative iontophoretic study with LSD and serotonin. Neuropharmacology. 1977;16(12):811–8.CrossRef
16.
Di Bella L, Rossi M, Scalera G. Perspectives in pineal functions. Progress in brain research. ‎Amsterdam: Elsevier; 1979. p. 475–8.
17.
Anwar MM, Mahfouz HA, Sayed AS. Potential protective effects of melatonin on bone marrow of rats exposed to cytotoxic drugs. Comp Biochem Physiol A Mol Integr Physiol. 1998;119(2):493–501.CrossRefPubMed
18.
Pablos M, Guerrero J, Ortiz G, Agapito M, Reiter R. Both melatonin and a putative nuclear melatonin receptor agonist CGP 52608 stimulate glutathione peroxidase and glutathione reductase activities in mouse brain in vivo. Int J Prenat Perinat Psychol Med. 1997;9(4):441–7.
19.
20.
Leon J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res. 2005;38(1):1–9.CrossRefPubMed
21.
Maestroni GJ, Zammaretti F, Pedrinis E. Hematopoietic effect of melatonin involvement of type 1K-opioid receptor on bone marrow macrophages and interleukin-1. J Pineal Res. 1999;27(3):145–53.CrossRefPubMed
22.
Greish K, Sanada I, Saad AED, Hasanin E, Kawasuji M, Kawano F, Maeda H. Protective effect of melatonin on human peripheral blood hematopoietic stem cells against doxorubicin cytotoxicity. Anticancer Res. 2005;25(6B):4245–8.PubMed
23.
Kundurović Z, Sćepović M. Histoenzymological reactions of the thyroid gland in irradiated and previously melatonin-treated irradiated rats. Acta Med Iugosl. 1989;43(5):337–47.PubMed
24.
Lane EA, MOSS HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab. 1985;61(6):1214–6.CrossRefPubMed
25.
Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. 1997;89(7):2303–10.PubMed
26.
Lissoni P, Bucovec R, Bonfanti A, Giani L, Mandelli A, Roselli M, et al. Thrombopoietic properties of 5-methoxytryptamine plus melatonin versus melatonin alone in the treatment of cancer-related thrombocytopenia. J Pineal Res. 2001;30(2):123–6.CrossRefPubMed
27.
Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. Effects of melatonin on human mood and performance. Brain Res. 1984;323(2):201–7.CrossRefPubMed
28.
Voordouw B, Euser R, Verdonk RE, Alberda BT, de Jong FH, Drogendijk AC, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab. 1992;74(1):108–17.PubMed
29.
Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. Br Med J (Clin Res Ed.). 1986;292(6529):1170.CrossRef
30.
Neri B, Fiorelli C, Moroni F, Nicita G, Paoletti MC, Ponchietti R, et al. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study. Cancer. 1994;73(12):3015–9.CrossRefPubMed
31.
Martín F, Atienza G, Aldegunde M, Míguez J. Melatonin effect on serotonin uptake and release in rat platelets: diurnal variation in responsiveness. Life Sci. 1993;53(13):1079–87.CrossRefPubMed
32.
Valevski A, Modal I, Jerushalmy Z, Kikinzon L, Weizman A. Effect of melatonin on active transport of serotonin into blood platelets. Psychiatr Res. 1995;57(2):193–6.CrossRef
33.
Reiter RJ, Herman TS, Meltz ML. Melatonin and radioprotection from genetic damage: in vivo/in vitro studies with human volunteers. Mutat Res Genet Toxicol. 1996;371(3–4):221–8.
34.
Singh N, Manshian B, Jenkins GJ, Griffiths SM, Williams PM, Maffeis TG, et al. NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials. 2009;30(23–24):3891–914.CrossRef
35.
Tesoriere L, D’arpa D, Conti S, Giaccone V, Pintaudi A, Livrea M. Melatonin protects human red blood cells from oxidative hemolysis: new insights into the radical-scavenging activity. J Pineal Res. 1999;27(2):95–105.CrossRefPubMed
36.
Bułdak RJ, Pilc-Gumuła K, Bułdak Ł, Witkowska D, Kukla M, Polaniak R, et al. Effects of ghrelin, leptin and melatonin on the levels of reactive oxygen species, antioxidant enzyme activity and viability of the HCT 116 human colorectal carcinoma cell line. Mol Med Rep. 2015;12(2):2275–82.CrossRefPubMed
37.
Wei JY, Li WM, Zhou LL, Lu QN, He W. Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J Pineal Res. 2015;58(4):429–38.CrossRefPubMed
38.
Stefano A, Paulesu L. Inhibitory effect of melatonin on production of IFNγ or TNFα in peripheral blood mononuclear cells of some blood donors. J Pineal Res. 1994;17(4):164–9.CrossRefPubMed
39.
Garcia-Mauriño S, Gonzalez-Haba MG, Calvo JR, Goberna R, Guerrero JM. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J Neuroimmunol. 1998;92(1):76–84.CrossRefPubMed
40.
Nemeth C, Humpeler S, Kallay E, Mesteri I, Svoboda M, Rögelsperger O, et al. Decreased expression of the melatonin receptor 1 in human colorectal adenocarcinomas. J Biol Regul Homeost Agents. 2011;25(4):531–42.PubMed
41.
Koc M, Buyukokuroglu ME, Taysi S. The effect of melatonin on peripheral blood cells during total body irradiation in rats. Biol Pharm Bull. 2002;25(5):656–7.CrossRefPubMed
42.
Karbownik M, Reiter RJ. Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation. Proc Soc Exp Biol Med. 2000;225(1):9–22.CrossRefPubMed
Metadata
Title
The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial
Authors
N. Kouhi Habibi
A. Shabestani Monfared
K. Ebrahimnejad Gorji
M. Karimi
A. A. Moghadamnia
M. Tourani
S. Borzoueisileh
F. Niksirat
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1977-2

Other articles of this Issue 6/2019

Clinical and Translational Oncology 6/2019 Go to the issue

Research Article

Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Brief Research Article

Statin treatment and outcomes of metastatic pancreatic cancer: a pooled analysis of two phase III studies

Research Article

Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer

Research Article

The burden of cancer in Spain

Review Article

Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives

Research Article

Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits